Editas Medicine, Inc. Profile Avatar - Palmy Investing

Editas Medicine, Inc.

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops …

Biotechnology
US, Cambridge [HQ]
Revenue Breakdowns

Segment Analysis Beta

The financial segments are sourced from the SEC' 10-K statement.

Revenue By Top Segments

Editas Medicine, Inc. can't present it's sankey chart.

Historical Revenue By Segment

Last 3Y, in million USD

Editas Medicine, Inc. can't present revenue by segment

End of EDIT's Analysis
CIK: 1650664 CUSIP: 28106W103 ISIN: US28106W1036 LEI: - UEI: -
Secondary Listings
EDIT has no secondary listings inside our databases.